News

Open

Advertisement

News

1-20 of 2961 results
1 2 3 4 5 Next »

FDA Panel Thoroughly Discusses TriGUARD 3 Market Application

Aug 03, 2021 by
Jason Wermers, CRTonline.org

The TriGUARD 3 Cerebral Embolic Protection Device is designed to minimize the risk of cerebral damage by deflecting embolic debris away from cerebral circulation during transcatheter aortic valve replacement (TAVR), but there is no evidence that it actually accomplishes that, according to the consensus of a U.S. Food and Drug Administration (FDA) advisory panel.

Redo TAVR Superior to Explantation at 30 Days, Similar at 1 Year – Analysis of Medicare Patients

Aug 02, 2021 by
Mohit Pahuja, CRTonline.org

Repeat transcatheter aortic valve replacement (TAVR) procedures in high-risk patients showed an “acceptable” 30-day mortality rate, with short-term outcomes superior to those of surgical explantation of transcatheter heart valves but similar 1-year outcomes, according to a new analysis of Medicare patients.

Asymptomatic Intracranial Atherosclerotic Stenosis Associated with High Rates of Cerebral, Systemic Vascular Events

Aug 02, 2021 by
Nathan Gray, CRTonline.org

An incidental diagnosis of asymptomatic intracranial atherosclerotic stenosis (ICAS) should trigger a thorough assessment of vascular health, a new analysis of population data suggests.

Multicenter Registry Data Confirm Post-TPVR Endocarditis Risks

Aug 02, 2021 by
Nathan Gray, CRTonline.org

Findings from a new international registry to characterize endocarditis after transcatheter pulmonary valve replacement (TPVR) will be critical to understanding and reducing future risks and improving patient outcomes, say those behind the study.

Machine-Learning Study Identifies CMR Risk Markers in Patients with Aortic Stenosis

Aug 02, 2021 by
Nathan Gray, CRTonline.org

A machine-learning analysis of patients with severe aortic stenosis (AS) undergoing aortic valve replacement (AVR) has identified multiple risk markers from cardiovascular magnetic resonance (CMR).

NCDR Analysis: Rise in Same-Day Discharge Post-PCI Not Associated With Worse Outcomes

Aug 02, 2021 by
Natalie Morrison, CRTonline.org

A decade-long analysis of more than 800,000 patients undergoing elective procedures in almost 2,000 U.S. hospitals shows that an increase in same-day discharge following elective percutaneous coronary intervention (PCI) did not result in worse 30-day mortality or rehospitalization.

State-of-the-Art Review: Antithrombotic Therapy Guidelines Specific to Individual Ischemic and Bleeding Risks An ‘Unmet Need’ in TAVR

Aug 02, 2021 by
Natalie Morrison, CRTonline.org

There is an “unmet need” for antithrombotic therapy guidelines that are specific to the individual ischemic and bleeding risk of patients in the setting of transcatheter aortic valve replacement (TAVR), according to a new state-of-the-art review.

Long-Term South Korean Registry Data: Angio-IMR, Wire-Derived IMR Show Similar Diagnostic Accuracy in STEMI Patients

Aug 02, 2021 by
Natalie Morrison, CRTonline.org

Angiography-derived index of microcirculatory resistance (angio-IMR) showed high correlation and diagnostic accuracy to predict wire-derived IMR in a new 10-year post-percutaneous coronary intervention (PCI) South Korean registry study and showed those with angio-IMR >40 U were at significantly greater risk.

1-Month DAPT Noninferior to Standard DAPT in Patients Not at High Bleeding Risk – Korean Randomized Trial

Jul 28, 2021 by
Sukhdeep Bhogal, CRTonline.org

Aspirin monotherapy following 1 month of dual antiplatelet therapy (DAPT) after polymer-free drug-coated stent (PF-DCS) implantation is non-inferior to 6 to 12 months of DAPT after biodegradable-polymer drug-eluting stent (BP-DES) implantation in a patient population that is not exclusively high bleeding risk, according to trial results released Wednesday.

NRD Analysis: TEER with MitraClip ‘Reasonable’ Option to Treat Patients with Shock, MR

Jul 28, 2021 by
Amer Aladin, CRTonline.org

Urgent transcatheter edge-to-edge repair (TEER) with the MitraClip may be a reasonable treatment choice in patients with cardiogenic shock (CS) and significant mitral regurgitation (MR), even though it is associated with high mortality and hospital readmission rates, a new Nationwide Readmissions Database (NRD) analysis suggests.

PCSK9 Inhibition May Provide Clinical Benefit When Lipoprotein(a) Is Elevated in Recent ACS Patients: Post Hoc Analysis

Jul 26, 2021 by
Nathan Gray, CRTonline.org

Proprotein subtilisin/kexin type 9 (PCSK9) inhibitors such as alirocumab may provide clinical benefits in patients with low-density lipoprotein cholesterol (LDL-C) levels near 70 mg/dL and recent acute coronary syndromes (ACS) only when lipoprotein(a), or Lp(a), is elevated, a post hoc analysis of trial data suggests.

New EMPA-TROPISM Analysis Finds Empagliflozin Significantly Improved Heart Failure Factors in Nondiabetics

Jul 26, 2021 by
Natalie Morrison, CRTonline.org

A new analysis of the EMPA-TROPISM trial found the sodium-glucose cotransporter-2 (SGLT2) receptor inhibitor empagliflozin significantly improved adiposity, interstitial myocardial fibrosis, aortic stiffness, and inflammatory markers in nondiabetic patients with heart failure with reduced ejection fraction (HFrEF).

ARIC Analysis: Delaying Diabetes Onset Could Be Heart Failure Prevention Strategy

Jul 26, 2021 by
Natalie Morrison, CRTonline.org

Delaying diabetes onset could aid prevention efforts for incident heart failure, according to a new analysis of ARIC data.

Study: Novel Variant of Lipoprotein(a) Gene May Be Present in up to 40% of Population

Jul 26, 2021 by
Nathan Gray, CRTonline.org

A newly identified genetic variant coding for lipoprotein(a), or Lp(a), may be present in 40% of the population, and has an important impact on risk of coronary artery disease (CAD), a new analysis reports.

State-of-the-Art Review: Analysis of Individual Heart Failure Risk Factors in Diabetes Elucidates Role of SGLT2 Inhibition

Jul 26, 2021 by
Natalie Morrison, CRTonline.org

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may mitigate each of the mechanisms of heart failure in diabetics; these mechanisms are probably mediated through hyperinsulinemia for those with type 2 disease, according to a new state-of-the-art review.

Reverse Potts Shunt Provides Significant Clinical Improvement in Children with Severe Pulmonary Hypertension

Jul 26, 2021 by
Nathan Gray, CRTonline.org

The placement of a pulmonary-to-systemic arterial shunt – otherwise known as a reverse Potts shunt – can provide a child with severe pulmonary hypertension (PH) significant improvement that is both durable and potentially free from continuous prostacyclin infusion, repository data suggest.

COAPT Analysis: MitraClip ‘Did Not Modify Association’ Between Rehospitalization, Subsequent Death

Jul 22, 2021 by
Matthew Litman and Jason Wermers, CRTonline.org

A new analysis of the COAPT trial revealed that, the lower rate of rehospitalization among patients with moderate-to-severe or severe mitral regurgitation (MR) secondary to heart failure (HF) treated with MitraClip and maximally tolerated guideline-directed medical therapy (GDMT) did not have an effect on the MitraClip patients’ lower mortality rate as compared to patients who received GDMT alone.

Patients With Aborted TEER Have Worse Outcomes After Mitral Valve Surgery Than Those With Acute or Delayed TEER Failure – CUTTING-EDGE Registry

Jul 22, 2021 by
Giorgio A. Medranda, CRTonline.org

Among patients for whom transcatheter edge-to-edge repair (TEER) for symptomatic moderate-to-severe or severe mitral regurgitation (MR) was attempted but failed (aborted, acute failure or delayed failure) necessitating mitral valve surgery, those with aborted TEER saw worse outcomes, according to late-breaking trial results presented Tuesday at Transcatheter Valve Therapies (TVT) 2021.

Registry Analysis: Transseptal Mitral Valve-in-Ring Might Be Reasonable Alternative for High-Risk Patients

Jul 21, 2021 by
Amer Aladin, CRTonline.org

Mitral valve-in-ring (MViR) procedures performed via transseptal access show lower-than-expected 30-day mortality rates, making this a reasonable alternative for high-surgical-risk patients, according to late-breaking trial results presented Wednesday at Transcatheter Valve Therapies 2021 in Miami Beach, Florida

MAC Shows Worse Periprocedural Mitral Intervention Outcomes, but TMVI Appears to Improve Technical, Clinical Results – Registry

Jul 21, 2021 by
Sukhdeep Bhogal, CRTonline.org

The presence of mitral annular calcification (MAC) confers worse periprocedural outcomes that last beyond 30 days, but transcatheter mitral valve implantation (TMVI) appears to improve technical and clinical outcomes compared to other transcatheter-based techniques, according to late-breaking trial results presented Wednesday at Transcatheter Valve Therapies (TVT) 2021.

1-20 of 2961 results
1 2 3 4 5 Next »

CRTonline on Facebook

CRT Meeting

CRTonline on Twitter

Tweets by CRT_meeting

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

CRTonline on Facebook

CRTonline on Twitter

Explore the Site

Stay Connected